Accent Therapeutics is a biopharmaceutical company based in New York, specializing in the development of inhibitory molecule drugs within the field of epitranscriptomics. The company's mission is to advance the understanding and treatment of diseases by targeting RNA-modifying proteins. Accent Therapeutics focuses on creating innovative therapies that can address unmet medical needs, particularly in oncology.
The company has made significant strides in its research and development efforts, presenting data on its two lead programs at the American Association for Cancer Research (AACR) Annual Meeting. These programs target DHX9 and KIF18A, which have been identified as compelling therapeutic targets. Accent Therapeutics' work has garnered attention within the scientific community, contributing to the broader understanding of cancer treatment and enhancing the potential for new, effective therapies.
